度拉糖肽对卒中影响:REWIND试验的探索性分析
REWIND试验为多中心随机双盲安慰剂对照研究,纳入9901例2型糖尿病伴心血管风险患者,比较每周度拉糖肽1.5mg与安慰剂。中位随访5.4年,度拉糖肽组卒中发生率3.2% vs 安慰剂组4.1%(HR 0.76,95%CI 0.62-0.94;P=0.010),主要降低缺血性卒中,对出血性卒中无影响,未改变卒中后残疾程度。
要点
- 度拉糖肽组卒中发生率3.2% vs 安慰剂组4.1%,HR 0.76(95%CI 0.62-0.94;P=0.010)。
- 度拉糖肽降低缺血性卒中(HR 0.75,95%CI 0.59-0.94;P=0.012),对出血性卒中无影响(HR 1.05,95%CI 0.55-1.99;P=0.89)。
- 度拉糖肽降低非致死性卒中或全因死亡复合终点(HR 0.88,95%CI 0.79-0.98;P=0.017)及致残性卒中(HR 0.74,95%CI 0.56-0.99;P=0.042)。
核心结论
- 长期使用度拉糖肽可能减少2型糖尿病患者的临床相关缺血性卒中,但不影响卒中严重程度。
研究设计与样本
- REWIND为多中心、随机、双盲、安慰剂对照试验,在24个国家371个中心进行。
- 纳入年龄≥50岁、确诊或新诊断2型糖尿病且HbA1c≤9.5%、BMI≥23 kg/m²、接受稳定剂量至多两种口服降糖药伴或不伴基础胰岛素治疗的患者。
- 共筛查12133例,随机分配9901例至度拉糖肽1.5mg每周皮下注射组(n=4949)或等体积安慰剂组(n=4952)。
- 主要终点为非致死性心肌梗死、非致死性卒中或心血管/不明原因死亡的复合终点首次发生。
- 所有分析按意向性治疗策略进行,纳入所有随机分配参与者。
主要发现
- 中位随访5.4年,度拉糖肽组158/4949例(3.2%)发生卒中,安慰剂组205/4952例(4.1%)发生卒中(HR 0.76,95%CI 0.62-0.94;P=0.010)。
- 度拉糖肽降低缺血性卒中(HR 0.75,95%CI 0.59-0.94;P=0.012),对出血性卒中无影响(HR 1.05,95%CI 0.55-1.99;P=0.89)。
- 度拉糖肽降低非致死性卒中或全因死亡复合终点(HR 0.88,95%CI 0.79-0.98;P=0.017)和致残性卒中(HR 0.74,95%CI 0.56-0.99;P=0.042)。
- 卒中后残疾程度在治疗组间无差异。
临床怎么用
- 作者认为,长期使用度拉糖肽可能减少2型糖尿病患者的临床相关缺血性卒中,但不影响卒中严重程度。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cardiovascular outcome trials have suggested that glucagon-like peptide 1 (GLP-1) receptor agonists might reduce strokes. We analysed the effect of dulaglutide on stroke within the researching cardiovascular events with a weekly incretin in diabetes (REWIND) trial. METHODS: REWIND was a multicentre, randomised, double-blind, placebo-controlled trial done at 371 sites in 24 countries. Men and women (aged ≥50 years) with established or newly detected type 2 diabetes whose HbA1c was 9·5% or less (with no lower limit) on stable doses of up to two oral glucose-lowering drugs with or without basal insulin therapy were eligible if their body-mass index was at least 23 kg/m2. Participants were randomly assigned (1:1) to weekly subcutaneous injections of either masked dulaglutide 1·5 mg or the same volume of masked placebo (containing the same excipients but without dulaglutide). Randomisation was done by a computer-generated random code with an interactive web response system with stratification by site. Participants, investigators, the trial leadership, and all other personnel were masked to treatment allocation until the trial was completed and the database was locked. During the treatment period, participants in both groups were instructed to inject study drug on the same day at around the same time, each week. Strokes were categorised as fatal or non-fatal, and as either ischaemic, haemorrhagic, or undetermined. Stroke severity was assessed using the modified Rankin scale. Participants were seen at 2 weeks, 3 months, 6 months, and then every 3 months for drug dispensing and every 6 months for detailed assessments, until 1200 confirmed primary outcomes accrued. The primary endpoint was the first occurrence of any component of the composite outcome, which comprised non-fatal myocardial infarction, non-fatal stroke, or death from cardiovascular or unknown causes. All analyses were done according to an intention-to-treat strategy that included all randomly assigned participants, irrespective of adherence. The trial is registered with ClinicalTrials.gov, number NCT01394952. FINDINGS: Between Aug 18, 2011, and Aug 14, 2013, we screened 12 133 patients, of whom 9901 with type 2 diabetes and additional cardiovascular risk factors were randomly assigned to either dulaglutide (n=4949) or an equal volume of placebo (n=4952). During a median follow-up of 5·4 years, cerebrovascular and other cardiovascular outcomes were ascertained and adjudicated. 158 (3·2%) of 4949 participants assigned to dulaglutide and 205 (4·1%) of 4952 participants assigned to placebo had a stroke during follow-up (hazard ratio [HR] 0·76, 95% CI 0·62-0·94; p=0·010). Dulaglutide reduced ischaemic stroke (0·75, 0·59-0·94, p=0·012) but had no effect on haemorrhagic stroke (1·05, 0·55-1·99; p=0·89). Dulaglutide also reduced the composite of non-fatal stroke or all-cause death (0·88, 0·79-0·98; p=0·017) and disabling stroke (0·74, 0·56-0·99; p=0·042). The degree of disability after stroke did not differ by treatment group. INTERPRETATION: Long-term dulaglutide use might reduce clinically relevant ischaemic stroke in people with type 2 diabetes but does not affect stroke severity. FUNDING: Eli Lilly and Company.
引用
- Gerstein HC, Hart R, Colhoun HM, et al. The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial. Lancet Diabetes Endocrinol. 2020. PMID: 31924562. doi:10.1016/S2213-8587(19)30423-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。